Telix Pharmaceuticals Limited

Telix today announces it has submitted a New Drug Application (NDA) to the FDA for TLX101-CDx (Pixclara®), an investigational PET agent for the characterisation of progressive or recurrent glioma (brain cancer) in both adult and pediatric patients. Gliomas are the most common primary brain tumours of the central nervous system, however conventional imaging with MRI often yields inconclusive results and can delay time-sensitive decision-making. TLX101-CDx has the potential to address a critical unmet need to improve diagnosis and management of this disease, particularly in the post-treatment setting. Read more on our website here: https://bit.ly/4g4XzY4

Telix today unveils a new organisational structure, reflecting our focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model is designed to optimise the development and commercialisation of theranostic radiopharmaceuticals. We are also pleased to announce new leadership appointments for Kevin Richardson, Richard Valeix and Raphaël (Raph) ORTIZ, and congratulate our colleagues who have taken on new roles at Telix, as we embark on our next phase of evolution. To read the full announcement, visit our website here: https://lnkd.in/gpWE3RA6

Telix has released its results for the half-year ended 30 June 2024. H1 2024 saw Telix continue to grow revenue from Illuccix® with achievements across the theranostic pipeline and in supply chain and manufacturing, positioning the Company for future growth on multiple fronts. To learn more about the results, visit our website, where you can also register for an investor webcast tomorrow morning AEST, later today in Europe and the US: https://bit.ly/3yNAGrv

Telix is pleased to support the #APCC24 Conference taking place next week in Melbourne, Australia. The event will feature four Telix-sponsored sessions delivered by internationally recognised oncologist and ProstACT GLOBAL investigator, Professor Scott Tagawa, MD, delving into the latest advances in prostate cancer theranostics. ⚛️ Review of targeted radionuclide therapy (TRT) for prostate cancer ⚛️ Lutetium - who and when? ⚛️ Is there a role for mets directed therapy in castrate resistant prostate cancer (CRPC)? ⚛️ Novel prostate-specific membrane antigen (PSMA) targeted therapies To view the full program visit the APCC website here: https://lnkd.in/e-jNAJq7 Australian Prostate Centre

Telix will release its Half-Year 2024 results on Thursday 22 August. An investor webcast will be held at 9:00am AEST on Friday 23 August to present financial results and a business update Investors are invited to register for the webcast via our website: https://lnkd.in/gzY8MYvH

An investigator-initiated trial supported by Lightpoint has highlighted the safety profile and early feasibility of using SENSEI® with a 99mTc-PSMA-targeted tracer for the intraoperative detection of metastatic lymph nodes in primary prostate cancer, prior to robot-assisted radical prostatectomy. Building on previous results for sentinel node biopsy, the publication demonstrates the utility of Lightpoint’s drop in gamma probe at initial diagnosis, potentially broadening the application of this technology in the disease, where radioguided surgery with this tracer has typically been performed in the recurrent setting. Further research is now being conducted to confirm the ability of SENSEI and targeted radiation imaging agents to detect micrometastatic prostate cancer during surgery as well as exploring their use in other urologic and non-urologic malignancies. Read the paper below or visit https://lnkd.in/dekia9t for more on Lightpoint and SENSEI

We are pleased to announce that the outcome of a joint research project with the University of Sydney has been selected for publication as a cover story in the latest edition of Chemical Science Journal, the flagship journal for Royal Society of Chemistry. This research represents the culmination of a highly successful academic-industry collaboration and innovation, stemming from early conversations between Professor Rachel Codd and Telix Chief Scientist, Michael Wheatcroft, about future improvements that could complement the burgeoning field of theranostics. As a result, Rachel Codd and co-workers developed a proprietary, first-in-class, dual-chelator technology that can deliver either therapeutic or diagnostic radiation to a tumour, when attached to a monoclonal antibody. By designing a single agent to bind complementary diagnostic and therapeutic radiometal pairs of radioisotopes, this platform technology aims to streamline future development pathways and improve patient dosimetry in theranostics, an increasingly important direction of cancer care.  We are excited to continue this collaboration; to drive this platform technology, which has shown such promise in preclinical studies, to clinical translation and commercialisation. Read the full article here: https://lnkd.in/gSsGErht

This week marked World Day against Trafficking in Persons, shining a spotlight on this important issue. Against this background, Telix has released an update to its Modern Slavery Statement. Visit our website to learn more about Telix's commitment to the protection of human rights: https://bit.ly/3LNLbxN

Join Telix’s Director of Global Patient Advocacy and Government Affairs, Simone Leyden AM, and other expert panelists to explore how personalised medicine, including theranostics, can deliver better results for patients. 

Telix is pleased to support the 3rd Annual Targeted Radiopharmaceuticals Summit US, which has started today in San Diego, CA. This event brings together key commercial and scientific industry leaders, to discuss the future of radiopharmaceuticals. Telix is featured on the line-up of expert speakers, exploring innovation in the sector from clinical development and trial design, to manufacturing and supply chain optimisation. To view the full event guide, visit: https://lnkd.in/eXjc43na #TRPSummit2024 #Radiopharmaceuticals